A Pilot Randomized Tissue-Based Study Evaluating Anti-PD1 Antibody or Anti-PD1 + Bevacizumab or Anti-PD1 + Anti-CTLA-4 in Patients With Metastatic Renal Cell Carcinoma Who Are Eligible for Cytoreductive Nephrectomy, Metastasectomy or Post-Treatment Biopsy
Active, no longer recruiting
Phase of Trial: Phase 0
Latest Information Update: 24 Apr 2018
At a glance
- Drugs Bevacizumab (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Renal cancer
- Focus Adverse reactions
- 18 Apr 2018 Status changed from recruiting to active, no longer recruiting.
- 05 Feb 2018 Planned End Date changed from 1 Nov 2019 to 1 Nov 2020.
- 03 Aug 2017 Planned End Date changed from 1 Nov 2018 to 1 Nov 2019.